The application of COX-2 inhibitors has been shown to alleviate BPH symptoms [35, 36], reviewed in [37], suggesting that overexpression of the COX-2 enzyme and certain PTGS2 gene alleles may be related to BPH risk. This evidence concerns the gene PTGS2 and benign prostatic hyperplasia.